Get the Stockscreener App
33.45
1.96%
-0.67
Castle Biosciences Inc stock is traded at $33.45, with a volume of 484.16K.
It is down -1.96% in the last 24 hours and up +49.60% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$34.12
Open:
$33.02
24h Volume:
484.16K
Relative Volume:
1.21
Market Cap:
$970.33M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-15.56
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
+1.24%
1M Performance:
+49.60%
6M Performance:
+104.96%
1Y Performance:
+8.50%
1-Day Range:
$32.96
$33.97
1-Week Range:
$32.51
$35.49
52-Week Range:
$14.59
$35.49
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
33.45 | 995.92M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
578.71 | 217.96B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
221.21 | 156.24B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
689.93 | 56.01B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.82 | 41.64B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
220.61 | 38.07B | 15.90B | 1.28B | 2.21B | 7.2842 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Will Castle Biosciences Inc. stock remain a Wall Street favorite2025 Volatility Report & Reliable Trade Execution Plans - newser.com
Castle Biosciences Inc. recovery potential after sell off2025 Biggest Moves & AI Driven Stock Reports - newser.com
Advisors Capital Management LLC Purchases 44,180 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Full technical analysis of Castle Biosciences Inc. stockEarnings Miss & Breakout Confirmation Alerts - newser.com
Is Castle Biosciences Inc. stock a dividend growth opportunity2025 Buyback Activity & Fast Gain Stock Trading Tips - newser.com
Quantitative breakdown of Castle Biosciences Inc. recent moveForecast Cut & Fast Exit/Entry Strategy Plans - newser.com
Is Castle Biosciences Inc a good long term investmentMarket Liquidity Analysis & High Profit Growth Stocks - earlytimes.in
Evaluating Castle Biosciences Inc. with trendline analysisPortfolio Performance Report & High Accuracy Buy Signal Tips - newser.com
Castle Biosciences melanoma test shows improved risk prediction By Investing.com - Investing.com Nigeria
Pattern recognition hints at Castle Biosciences Inc. upsideBond Market & Capital Efficient Trading Techniques - newser.com
Why Castle Biosciences Inc. stock could be next big winnerQuarterly Investment Review & AI Powered Buy and Sell Recommendations - Fundação Cultural do Pará
Castle Biosciences (CSTL) Showcases Breakthrough in Melanoma Tes - GuruFocus
Castle Biosciences Announces Clinical Data Supporting DecisionDx-Melanoma's Role in Sentinel Lymph Node Biopsy Decision Making at ECDO 2025 - Quiver Quantitative
Can Castle Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Insider Sell: Frank Stokes Sells Shares of Castle Biosciences In - GuruFocus
Chart based analysis of Castle Biosciences Inc. trends2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Zacks.com featured highlights include Castle Biosciences, Perimeter Solutions, South Atlantic Bancshares and Astronics - sharewise.com
Acadian Asset Management LLC Has $11.11 Million Stock Position in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Reaches New 52-Week HighHere's Why - MarketBeat
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Is Castle Biosciences Ready To Turn Stability Into Growth? - RTTNews
When is the best time to exit Castle Biosciences Inc.New Guidance & Capital Efficiency Focused Strategies - newser.com
Is Castle Biosciences Inc. stock attractive for income investors2025 Key Lessons & Consistent Growth Equity Picks - newser.com
Castle Biosciences CEO Maetzold sells $289k in shares By Investing.com - Investing.com Philippines
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,695 Shares of Stock - MarketBeat
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million - Lelezard
Scibase and Castle Biosciences enter into loan agreement of SEK 20 million - MarketScreener
Scibase and Castle Biosciences expand collaboration - MarketScreener
Statistical indicators supporting Castle Biosciences Inc.’s strengthTrade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
Castle Biosciences CEO Maetzold sells $289k in shares - Investing.com India
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):